{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:26:49Z","timestamp":1792610809962,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cmi.2025.10.011","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T23:03:39Z","timestamp":1761433419000},"page":"185-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tetracycline hydrochloride susceptibility for prediction of antimicrobial susceptibility to doxycycline, minocycline, and tigecycline against Gram-negative and Gram-positive bacteria"],"prefix":"10.1016","volume":"32","author":[{"given":"Maroun M.","family":"Sfeir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.10.011_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/biom14070783","article-title":"Third-generation tetracyclines: Current knowledge and therapeutic potential","volume":"14","author":"Kounatidis","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.cmi.2025.10.011_bib2","doi-asserted-by":"crossref","first-page":"a025387","DOI":"10.1101\/cshperspect.a025387","article-title":"Tetracycline antibiotics and resistance","volume":"6","author":"Grossman","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cmi.2025.10.011_bib3","series-title":"M100: performance standards for antimicrobial susceptibility testing","first-page":"Ed34","year":"2024"},{"key":"10.1016\/j.cmi.2025.10.011_bib4","series-title":"The European Committee on antimicrobial susceptibility testing","year":"2024"},{"key":"10.1016\/j.cmi.2025.10.011_bib5","series-title":"US Food and Drug Administration (FDA)-identified interpretive criteria breakpoints","year":"2024"},{"key":"10.1016\/j.cmi.2025.10.011_bib6","series-title":"Development of in vitro susceptibility testing criteria and quality control parameters","year":"2018"},{"key":"10.1016\/j.cmi.2025.10.011_bib7","unstructured":"U.S. FDA. Guidance for industry and FDA class II special controls guidance document: Antimicrobial susceptibility test (AST) systems. 2009. https:\/\/www.fda.gov. [Accessed 21 April 2025]."},{"key":"10.1016\/j.cmi.2025.10.011_bib8","series-title":"Verification of commercial microbial identification and antimicrobial susceptibility testing systems","year":"2015"},{"key":"10.1016\/j.cmi.2025.10.011_bib9","series-title":"Clinical laboratory testing and in vitro diagnostic test systems\u2014Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices","first-page":"20776","year":"2021"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:12:14Z","timestamp":1767996734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25005129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1198743X25005129"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.10.011","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetracycline hydrochloride susceptibility for prediction of antimicrobial susceptibility to doxycycline, minocycline, and tigecycline against Gram-negative and Gram-positive bacteria","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}